Viridian Therapeutics, Inc. (NASDAQ:VRDN) Stock Holdings Decreased by Virtus ETF Advisers LLC

Virtus ETF Advisers LLC lowered its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 43.6% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 3,952 shares of the company’s stock after selling 3,059 shares during the period. Virtus ETF Advisers LLC’s holdings in Viridian Therapeutics were worth $76,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. R Squared Ltd bought a new stake in shares of Viridian Therapeutics in the 4th quarter worth about $26,000. AlphaQuest LLC grew its position in shares of Viridian Therapeutics by 119.0% during the 4th quarter. AlphaQuest LLC now owns 2,795 shares of the company’s stock valued at $54,000 after buying an additional 1,519 shares during the last quarter. Summit Investment Advisors Inc. raised its stake in Viridian Therapeutics by 24.7% during the fourth quarter. Summit Investment Advisors Inc. now owns 7,646 shares of the company’s stock worth $147,000 after acquiring an additional 1,516 shares during the period. Quantbot Technologies LP acquired a new stake in Viridian Therapeutics during the fourth quarter worth about $164,000. Finally, KLP Kapitalforvaltning AS bought a new position in Viridian Therapeutics in the fourth quarter worth about $219,000.

Viridian Therapeutics Stock Up 0.2 %

Shares of Viridian Therapeutics stock opened at $13.53 on Tuesday. The business’s fifty day moving average price is $14.18 and its two-hundred day moving average price is $18.14. The company has a debt-to-equity ratio of 0.04, a current ratio of 18.55 and a quick ratio of 18.55. The company has a market capitalization of $1.10 billion, a P/E ratio of -3.14 and a beta of 0.81. Viridian Therapeutics, Inc. has a 1-year low of $9.90 and a 1-year high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN) last announced its earnings results on Thursday, February 27th. The company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($1.05) by $0.24. The firm had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.05 million. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. As a group, research analysts forecast that Viridian Therapeutics, Inc. will post -4.03 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on VRDN. Needham & Company LLC reiterated a “buy” rating and set a $38.00 price target on shares of Viridian Therapeutics in a research report on Tuesday, January 7th. HC Wainwright reissued a “buy” rating and issued a $34.00 price target on shares of Viridian Therapeutics in a report on Wednesday, April 23rd. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $35.70.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.